Daily non-political popular news in brief.
Scripps research combination therapy obliterates new vessel growth in tumors and retinopathy
01-09-2007 · EurekAlert!Using a new and dramatically effective treatment approach, scientists at the Scripps Research Institute have for the first time achieved complete inhibition of new blood vessel growth in animal models of a highly vascular brain tumor and of neovascular eye diseases with little or no effect on normal tissue vasculature.
Read more »
Keywords: scripps, research, combination, therapy, obliterates, vessel, growth, tumors, retinopathy, scripp, obliterate, tumor
« Previous | Next »
Similar news on "Scripps research combination therapy obliterates new vessel growth in tumors and retinopathy":
- Blood-vessel blocker aids cancer-killing virus
11-27-2007 · EurekAlert!
Cancer-killing viruses are a promising therapy for incurable brain tumors, but their effectiveness has been limited in part because immune cells rapidly eliminate them. That immune response might be slowed, and the virus given more time to kill cancer cells, by blocking the growth of blood vessels in the tumor, new Ohio State research suggests. The study indicates that pretreatment with a drug that blocks blood-vessel growth might improve the effectiveness of cancer-killing viruses.
Similar news · Read more »
- Combination therapy reduces tumor resistance to radiation
06-07-2007 · EurekAlert!
Radiation is used to treat a variety of tumors as it causes hypoxia and tumor cell death. Recently, radiation-induced hypoxia was shown to trigger tumor resistance to radiation via the activation of new blood vessel formation (angiogenesis). In a new JCI study, researchers show that a combination of radiation treatment and the use of angiogenesis inhibitors such as canstatin is able to overcome HIF-1-dependent tumor survival and increase tumor cell death in mice.
Similar news · Read more »
- JCI table of contents: June 7, 2007
06-07-2007 · EurekAlert!
This release contains summaries, links to PDFs, and contact information for the following newsworthy papers to be published online June 7, 2007, in the JCI, including: "Combination therapy reduces tumor resistance to radiation"; "Improved prediction of prostate cancer recurrence"; "Role of GM-CSF in the immune response to tumors"; "Protein C signaling impacts inflammatory bowel disease"; "Iron imbalance in anemia: Hints from HIF"; and "Phosphorylation state of eNOS is key to blood vessel function."
Similar news · Read more »
- Tumor-targeting viral therapy slows neuroblastoma, malignant peripheral nerve sheath tumors
02-15-2008 · EurekAlert!
Researchers in a multi-institutional study led by Cincinnati Children's Hospital Medical Center slowed the growth of two particularly stubborn solid tumor cancers -- neuroblastoma and peripheral nerve sheath tumors -- without harming healthy tissues by inserting instructions to inhibit tissue growth into an engineered virus, according to study results published in the Feb. 15 Cancer Research.
Similar news · Read more »
- Scientists follow familiar TRAIL to new cancer therapy
07-09-2007 · EurekAlert!
A new study identifies a combination therapy that may sensitize human cancer cells to a promising treatment currently being used in clinical trials. The research, published in the July issue of the journal Cancer Cell, published by Cell Press, provides a pharmacological method for enhancing the potency and effectiveness of a tumor necrosis factor death receptor ligand against a variety of human cancers.
Similar news · Read more »
- Penn researchers identify new combination therapy that promotes cancer cell death
07-16-2007 · EurekAlert!
To test the ability of combined therapy, researchers administered TRAIL, a tumor necrosis factor, and sorafenib, an inhibitor currently used to treat renal cancer, to mice with colon carcinomas. It reduced the size of tumors in mice with few side effects
Similar news · Read more »
- Growth factor signals influence balance between normal growth and cancerous growth
11-09-2006 · EurekAlert!
Too much of a signaling protein called insulin-like growth factor-I (IGF-I) may fan the flames of cancer, while too little of the protein may cause short stature, dementia and osteoporosis. New research investigates how the growth hormone/IGF system is affected by the important tumor suppressor gene p53. This interplay of two signaling pathways reinforces questions about the long-term risks of prescribing growth hormone, while suggesting a future new avenue for cancer therapy.
Similar news · Read more »
- Fat kills cancer
07-03-2007 · EurekAlert!
Researchers in Slovakia have been able to derive mesenchymal stem cells from human adipose, or fat, tissue and engineer them into "suicide genes" that seek out and destroy tumors like tiny homing missiles. This gene therapy approach is a novel way to attack small tumor metastases that evade current detection techniques and treatments, the researchers conclude in the July 1 issue of Cancer Research, a journal of the American Association for Cancer Research.
Similar news · Read more »
- Dual gene therapy suppresses lung cancer in preclinical test
01-15-2007 · EurekAlert!
Combination gene therapy delivered in lipid-based nanoparticles drastically reduces the number and size of human non-small cell lung cancer tumors in mice, researchers at The University of Texas M. D. Anderson Cancer Center and the University of Texas Southwestern Medical Center report in the January 15 edition of Cancer Research.
Similar news · Read more »
- FOXO factor promotes survival of oxygen-deprived cancer cells
12-27-2007 · EurekAlert!
Scientists report that an evolutionarily conserved transcription factor may have both positive and negative effects on the growth of tumors, depending on whether or not the tumor cells have enough oxygen. The research, published by Cell Press in the Dec. 28 issue of Molecular Cell, provides critical new information about how normal cells and cancer cells survive under stress.
Similar news · Read more »
